More than half of patients with chronic lymphocytic leukemia (CLL) who received ibrutinib for more than 3 years and had residual clonal lymphocytosis were found through next-generation sequencing to have a BTK mutation, and presence of this mutation was associated with subsequent disease progression, according to data from a FILO group study.1
“Mutational analyses performed following acquired ibrutinib resistance have suggested that CLL progression on ibrutinib is linked to mutations in the Bruton’s tyrosine kinase (BTK) and/or phospholipase Cg2 (PLCG2) genes,” researchers wrote. “However, mutational information for patients still on ibrutinib, without evidence of CLL progression, is limited.”
Therefore, in this study, researchers wanted to evaluate a group of real-life patients being treated with ibrutinib as part of an early-access program launched in 2014 that allowed for prolonged use of the drug.
Of 204 patients across 29 French Innovative Leukemia Organization (FILO) centers who were enrolled in the early-access program, 31% (63 patients) were still on ibrutinib after 3 years and were able to provide a fresh blood sample.
Of the 63 patients, 30 had a CLL clone of 0.5 x 109/L or greater and were able to undergo next-generation sequencing. At least one BTK mutation was present in 57% of samples, and PLCG2 mutations were found in 13% of samples.
With a median follow-up of 8.5 months from sample collection, those patients with a BTK mutation has significantly higher risk for CLL progression compared with patients who had no mutation (P =.0005).
“Our findings support that mutational analyses should be considered in patients receiving ibrutinib who have residual clonal lymphocytosis, and that clinical trials are needed to evaluate whether patients with a BTK mutation may benefit from an early switch to another treatment,” the researchers wrote.
Quinquenel A, Fornecker LM, Letestu R, et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after three years: FILO group study. [published online June 26, 2019]. Blood. doi: 10.1182/blood.2019000854
This article originally appeared on Cancer Therapy Advisor